Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.
Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on the induction of neutralizing antibodies against the major capsid protein, L1 of HPV. Cervarix() is one of the preventive HPV vaccines that has been approved in the Europe and Australia and is currently under review by the US Food and Drug Administration. Cervarix is composed of HPV16 and HPV18 L1 virus-like particles (VLPs) formulated in ASO4 adjuvant. Vaccination with Cervarix has been shown to protect women against a high proportion of precursor lesions of cervical cancer caused by these two HPV types. This review explores the various features of this new vaccine candidate and discusses the future directions in the field of HPV vaccine development.
Monie
Archana
A
Departments of Pathology.
Hung
Chien-Fu
CF
Roden
Richard
R
Wu
T-C
TC
J Virol. 1993 Jul;67(7):4154-62
7685411
J Virol. 1993 Jan;67(1):315-22
8380079
Mol Cell. 2000 Mar;5(3):557-67
10882140
J Gen Virol. 1994 Aug;75 ( Pt 8):2075-9
8046412
Virology. 2004 Jun 20;324(1):17-27
15183049
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11553-7
8524802
J Virol. 1996 Feb;70(2):960-5
8551636
J Infect Dis. 2001 May 15;183(10):1485-93
11319684
Virology. 2000 May 10;270(2):254-7
10792983
N Engl J Med. 2002 Nov 21;347(21):1645-51
12444178
Vaccine. 2006 Jul 7;24(27-28):5571-83
16753240
J Virol. 2007 Nov;81(21):11585-92
17715230
Nat Rev Cancer. 2002 May;2(5):342-50
12044010
J Adolesc Health. 2007 Jun;40(6):564-71
17531764
J Virol. 1995 Jun;69(6):3959-63
7745754
J Virol. 2004 Dec;78(23):12901-9
15542642
Nat Rev Cancer. 2006 Oct;6(10):753-63
16990853
J Virol. 1989 Nov;63(11):4898-903
2552162
Int J Cancer. 2004 Aug 20;111(2):278-85
15197783
Pediatrics. 2006 Nov;118(5):2135-45
17079588
Vaccine. 2006 Aug 14;24(33-34):5937-49
16828940
Virology. 1995 Jan 10;206(1):126-35
7831768
Obstet Gynecol. 2006 Jan;107(1):18-27
16394035
CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1
10200776
J Immunol. 2005 Mar 1;174(5):2476-80
15728450
Virology. 1995 Dec 20;214(2):349-59
8553535
Vaccine. 2004 Jul 29;22(21-22):2943-52
15246631
Infect Immun. 2004 Feb;72(2):750-6
14742517
Lancet. 2004 Nov 13-19;364(9447):1757-65
15541448
J Virol. 1997 Apr;71(4):2988-95
9060658
J Virol. 1998 Jul;72(7):6151-4
9621080
Lancet. 2007 Jun 30;369(9580):2161-2170
17602732
Curr Mol Med. 2007 Aug;7(5):490-503
17691964
Vaccine. 2004 Aug 13;22(23-24):3004-7
15297048
J Virol. 2002 Sep;76(17):8900-9
12163609
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4
1334560
Virology. 1992 Sep;190(1):548-52
1382345
Virology. 2001 May 10;283(2):353-7
11336560
Lancet. 2005 Sep 17-23;366(9490):991-8
16168781
Br J Cancer. 2006 Dec 4;95(11):1459-66
17117182
Lancet. 2006 Apr 15;367(9518):1247-55
16631880
Virology. 1996 May 1;219(1):37-44
8623552
Infect Immun. 1997 Aug;65(8):3328-36
9234794
J Virol. 2001 Sep;75(17):7848-53
11483728
J Virol. 2002 Oct;76(19):9798-805
12208958
Vaccine. 2004 Jul 29;22(21-22):2936-42
15246630
Vaccine. 2005 May 25;23(28):3634-41
15882523
J Natl Cancer Inst. 2001 Feb 21;93(4):284-92
11181775
Vaccine. 2006 Mar 15;24(12):2087-93
16343704
J Pathol. 1999 Sep;189(1):12-9
10451482